Subsequent Events |
6 Months Ended |
|---|---|
Jun. 30, 2021 | |
| Subsequent Events [Abstract] | |
| Subsequent Events |
NOTE 13 – SUBSEQUENT EVENTS In August 2021, the Company assumed full rights to TAK-169, including full control of TAK-169 clinical development, per the terms of the terminated Takeda Development and License Agreement, with its former TAK-169 co-development partner, Takeda. Following the transfer of the full TAK-169 rights to the Company, the Company will owe low-single digit royalties on future net sales of TAK-169 to Takeda as well as to certain third-party licensors. The Company will also owe certain third-party licensors potential aggregate clinical milestone payments of up to $22.25 million.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|